Assistant member, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center.
Member investigator, The Parker Institute for Cancer Immunotherapy.
Dr. Klebanoff is cellular immunologist and medical oncologist with 17 years of experience in the pre-clinical and clinical development of T cell-based immunotherapies for the treatment of solid and hematologic cancers. Prior to joining Memorial Sloan Kettering, he was an assistant clinical investigator and a NIH-Howard Hughes Medical Institute Research Scholar at the U.S. National Institutes of Health in Bethesda, MD.
As a member of the NCI Surgery Branch’s senior staff, he participated in the early phase clinical development of numerous T cell-based therapies which would later be licensed to commercial entities. These include the anti-CD19 28 CAR that would become Yescarta, gene engineered TCR therapies targeting NY-ESO-1, MAGE-A3/6, and HPV E6, and neoantigen selected TIL therapies for a diverse range of solid cancers.
Dr. Klebanoff’s laboratory investigations have contributed to the mechanistic understanding of how lymphodepletion enhances adoptive immunotherapies and how T cell differentiation status influences cellular persistence and clinical outcomes.